Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease

Cited by (1,002)

Items 101–200 of 1,002

1. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP)
   Francesco Locatelli, Adrian Constantin Covic, Kai‐Uwe Eckardt, Andrzej Więcek, Raymond Camille Vanholder, on behalf of the ERA-EDTA ERBP Advisory Board · 2008 · Nephrology Dialysis Transplantation
2. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
   Jodie L. Babitt, Michele Freerk Eisenga, Volker H. Haase, Abhijit V. Kshirsagar, Adeera Levin, Francesco Locatelli, Jolanta Małyszko, Dorine W. Swinkels, Der‐Cherng Tarng, Michael Cheung et al. · 2021 · Kidney International
3. Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease
   Marcello A. Tonelli, S. Ananth Karumanchi, Ravi Thadhani · 2016 · Circulation
4. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis
   Kai‐Uwe Eckardt, Rajiv Agarwal, Ahmad Aswad, Ahmed Awad, Geoffrey A. Block, Marcelo Rodrigues Bacci, Youssef M.K. Farag, Steven N. Fishbane, Harold Hubert, Alan G. Jardine et al. · 2021 · New England Journal of Medicine
5. Hemoglobin Variability and Mortality in ESRD
   Wei Peter Yang, Rubeen Israni, Steven M. Brunelli, Marshall M. Joffe, Steven Fishbane, Harold I. Feldman · 2007 · Journal of the American Society of Nephrology
6. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches
   Dirk Jan van Veldhuisen, Stefan D. Anker, Piotr P. Ponikowski, Iain C. Macdougall · 2011 · Nature Reviews Cardiology
7. The Many Facets of Erythropoietin Physiologic and Metabolic Response
   Sukanya Suresh, Praveen Kumar Rajvanshi, Constance Tom Noguchi · 2020 · Frontiers in Physiology
8. Review: Cognitive Function in Chronic Kidney Disease
   Magdalena Madero, Ambreen Gul, Mark J. Sarnak · 2007 · Seminars in Dialysis
9. Doença renal crônica: importância do diagnóstico precoce, encaminhamento imediato e abordagem interdisciplinar estruturada para melhora do desfecho em pacientes ainda não submetidos à diálise
   Marcus Gomes Bastos, Gianna Mastroianni Kirsztajn · 2011 · Brazilian Journal of Nephrology
10. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
    Nan Chen, Jiaqi Qian, Jianghua Chen, Xueqing Yu, Changlin Mei, Chuan‐Ming Hao, Gengru Jiang, Hongli Lin, Xinzhou Zhang, Li Zuo et al. · 2017 · Nephrology Dialysis Transplantation
11. Dose of Erythropoiesis-Stimulating Agents and Adverse Outcomes in CKD: A Metaregression Analysis
    Ioannis Koulouridis, Mansour Alfayez, Thomas A Trikalinos, Ethan M. Balk, Bertrand L. Jaber · 2012 · American Journal of Kidney Diseases
12. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications
    Zongzhong Tong, Zhenglin Yang, Shrena Patel, Haoyu Chen, Daniel Gibbs, Xian Qing Yang, Vincent S. Hau, Yuuki Kaminoh, Jennifer N. Harmon, Erik Pearson et al. · 2008 · Proceedings of the National Academy of Sciences
13. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach
    Clelia Madeddu, Giulia Gramignano, Giorgio Astara, Roberto Demontis, Elisabetta Sanna, Vinicio Atzeni, Antonio Macciò · 2018 · Frontiers in Physiology
14. Mechanisms of Disease: the hypoxic tubular hypothesis of diabetic nephropathy
    Dhruv K. Singh, Peter H. Winocour, Ken Farrington · 2008 · Nature Reviews Nephrology
15. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis
    Marcello A. Tonelli, Brenda R. Hemmelgarn, Tony Reiman, Braden Manns, Martin Neil Reaume, Anita M. Lloyd, Natasha Wiebe, Scott W Klarenbach · 2009 · Canadian Medical Association Journal
16. Four-Week Studies of Oral Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia
    Louis Holdstock, Amy M. Meadowcroft, Rayma Maier, Brendan Mark Johnson, Delyth Jones, Anjay Rastogi, Steven Zeig, John J. Lepore, Alexander R. Cobitz · 2015 · Journal of the American Society of Nephrology
17. Cardiorenal syndrome: pathophysiology and potential targets for clinical management
    Parta Hatamizadeh, Gregg C. Fonarow, Matthew Jay Budoff, Sirous Darabian, Csaba Pal Kovesdy, Kamyar Kalantar‐Zadeh · 2012 · Nature Reviews Nephrology
18. Heart failure in patients with kidney disease
    Courtney Tuegel, Nisha Bansal · 2017 · Heart
19. Through The Eyes of a Child: Understanding Retinopathy through ROP The Friedenwald Lecture
    Lois E. H. Smith · 2008 · Investigative Ophthalmology & Visual Science
20. Predictors of Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
    Kamyar Kalantar‐Zadeh, Grace H. Lee, Jessica Eden Miller, Elani Streja, Jennie Jing, John A. Robertson, Csaba Pal Kovesdy · 2009 · American Journal of Kidney Diseases
21. Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease
    Volker H. Haase · 2021 · Kidney International Supplements
22. Target Trial Emulation to Improve Causal Inference from Observational Data: What, Why, and How?
    Edouard L. Fu · 2023 · Journal of the American Society of Nephrology
23. Improving peripheral nerve regeneration: From molecular mechanisms to potential therapeutic targets
    Chan, K. Ming, Gordon, Tessa, Zochodne, Douglas W., Power, Hollie A. · 2014 · Experimental Neurology
24. Vascular Incompetence in Dialysis Patients—Protein‐Bound Uremic Toxins and Endothelial Dysfunction
    Noémie Jourde‐Chiche, Laetitia Dou, Claire Cérini, Françoise Dignat‐George, Philippe Brunet · 2011 · Seminars in Dialysis
25. Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis Patients
    Robert Provenzano, Brigitte M. Schiller, Madhumathi Rao, Daniel W. Coyne, Louis Brenner, Brian J.G. Pereira · 2009 · Clinical Journal of the American Society of Nephrology
26. Defining Medical Futility and Improving Medical Care
    Lawrence J. Schneiderman · 2011 · Journal of Bioethical Inquiry
27. Targeting the hepcidin–ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation
    Chia Chi Sun, Valentina Vaja, Jodie L. Babitt, Herbert Yih-Fuu Lin · 2011 · American Journal of Hematology
28. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience
    Neil S. Sanghani, Volker H. Haase · 2019 · Advances in Chronic Kidney Disease
29. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study
    Steven N. Fishbane, Mohamed A. El-Shahawy, Roberto Pecoits‐Filho, Bui Pham Van, Mark T. Houser, Lars Frison, Dustin J. Little, Nicolas Jose Guzman, Pablo E. Pérgola · 2021 · Journal of the American Society of Nephrology
30. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease
    Jessica Kendrick, Michel B. Chonchol · 2008 · Nature Reviews Nephrology
31. Critical and Honest Conversations
    Amy W. Williams, Amy C. Dwyer, Allison A. Eddy, Jeffrey Craig Fink, Bertrand L. Jaber, Stuart L. Linas, Beckie Michael, Ann M. O’Hare, Heidi M. Schaefer, Rachel N. Shaffer et al. · 2012 · Clinical Journal of the American Society of Nephrology
32. Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA)
    Krapf, Reto, Hulter, Henry N. · 2009 · Clinical Journal of the American Society of Nephrology
33. Ferric Gluconate Reduces Epoetin Requirements in Hemodialysis Patients with Elevated Ferritin
    Toros Kapoian, Neeta Bahal O’Mara, Ajay K. Singh, John Moran, Adel R. Rizkala, Robert P. Geronemus, Robert C. Kopelman, Naomi V. Dahl, Daniel W. Coyne · 2008 · Journal of the American Society of Nephrology
34. Hemoglobin Level Variability
    David T. Gilbertson, James P. Ebben, Robert N. Foley, Eric D. Weinhandl, Brian D. Bradbury, Allan J. Collins · 2007 · Clinical Journal of the American Society of Nephrology
35. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure
    Karien van der Putten, Branko G. Braam, Kim E. Jie, Sandrine Gaillard · 2007 · Nature Reviews Nephrology
36. Mechanisms Linking Red Blood Cell Disorders and Cardiovascular Diseases
    Ioana Monica Mozos · 2015 · BioMed Research International
37. Relation of Low Hemoglobin and Anemia to Morbidity and Mortality in Patients Hospitalized With Heart Failure (Insight from the OPTIMIZE-HF Registry)
    James B. Young, William T. Abraham, Nancy M. Albert, Wendy Gattis Stough, Mihai Gheorghiade, Barry Greenberg, Christopher M. O’Connor, Lilin She, Jie Lena Sun, Clyde W. Yancy et al. · 2008 · The American Journal of Cardiology
38. Cardiorenal Syndrome
    Ujjala Kumar, Nicholas W. Wettersten, Pranav Sandilya Garimella · 2019 · Cardiology Clinics
39. Hemodialysis‐induced cardiovascular disease
    Shadi Ahmadmehrabi, W.H. Wilson Tang · 2018 · Seminars in Dialysis
40. The Influence of Inflammation on Anemia in CKD Patients
    Anna Gluba-Brzózka, Beata Franczyk, Robert Olszewski, Jacek Rysz · 2020 · International Journal of Molecular Sciences
41. Does AKI Truly Lead to CKD?
    Dena E. Rifkin, Steven G. Coca, Kamyar Kalantar‐Zadeh · 2012 · Journal of the American Society of Nephrology
42. Fatigue in CKD
    L. Parker Gregg, Maurizio Bossola, Mauricio Ostrosky-Frid, S. Susan Hedayati · 2021 · Clinical Journal of the American Society of Nephrology
43. Cardiorenal Syndrome in Acute Decompensated Heart Failure
    Mohammad Sarraf, Amirali Masoumi, Robert W. Schrier · 2009 · Clinical Journal of the American Society of Nephrology
44. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)
    Francesco Locatelli, Allen R. Nissenson, Brendan J. Barrett, Rowan G. Walker, David Collins. Wheeler, Kai‐Uwe Eckardt, Norbert Hendrik Lameire, Garabed Eknoyan · 2008 · Kidney International
45. Health-Related Quality of Life and Hemoglobin Levels in Chronic Kidney Disease Patients
    Fredric O. Finkelstein, Kenneth O. Story, Catherine A. Firanek, David C. Mendelssohn, Paul E. Barré, Tomoko Takano, Steven Soroka, SALIM K. MUJAIS · 2008 · Clinical Journal of the American Society of Nephrology
46. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial
    Antonio Pisani, Eleonora Riccio, Massimo Sabbatini, Michele Andreucci, A. Del Rio, Bianca Visciano · 2014 · Nephrology Dialysis Transplantation
47. Evaluation and Long-Term Prognosis of New-Onset, Transient, and Persistent Anemia in Ambulatory Patients With Chronic Heart Failure
    W.H. Wilson Tang, Wilson S. Tong, Anil Jain, Gary S. Francis, C. Martin Harris, James B. Young · 2008 · Journal of the American College of Cardiology
48. Stage IV Chronic Kidney Disease
    Hanna E. Abboud, William L. Henrich · 2010 · New England Journal of Medicine
49. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study
    Hanny T. Al-Samkari, Raj S. Kasthuri, Joseph G. Parambil, Hasan Ahmad Hasan Albitar, Yahya A. Almodallal, Carolina Vázquez, Marcelo Martin Serra, Sophie Dupuis‐Girod, Craig B. Wilsen, Justin Pryce McWilliams et al. · 2020 · Haematologica
50. HIF‐prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism
    Volker H. Haase · 2017 · Hemodialysis International
51. Vascular Risk Factors and Cognitive Impairment in Chronic Kidney Disease
    Manjula Kurella Tamura, Dawei Xie, Kristine S. Yaffe, Debbie L. Cohen, Valerie L. Teal, Scott Eric Kasner, Steven Russell Messe, Ashwini R. Sehgal, John W. Kusek, Karen B. DeSalvo et al. · 2010 · Clinical Journal of the American Society of Nephrology
52. Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review
    Liviu Segall, Ionuţ Nistor, Adrian Constantin Covic · 2014 · BioMed Research International
53. Why we can't trust clinical guidelines
    Jeanne Lenzer · 2013 · BMJ
54. The erythropoietin receptor in normal and cancer tissues
    WOLFGANG E. B. JELKMANN, Julia Bohlius, Michael J. Hallek, Arthur J. Sytkowski · 2008 · Critical Reviews in Oncology/Hematology
55. Health-related quality of life outcomes in chronic kidney disease
    Ritu K Soni, Steven Darrow Weisbord, Mark L. Unruh · 2010 · Current Opinion in Nephrology & Hypertension
56. A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia
    Iain C. Macdougall, Jérôme Rossert, Nicole Casadevall, Richard B. Stead, Anne‐Marie Duliège, Marc Froissart, Kai‐Uwe Eckardt · 2009 · New England Journal of Medicine
57. Intravenous Ferric Carboxymaltose in Iron-Deficient Chronic Heart Failure Patients with and Without Anaemia: a Subanalysis of the FAIR-HF Trial
    Gerasimos S Filippatos, Dimitrios T. Farmakis, Josep Comin Colet, Kenneth Dickstein, Thomas Felix Lüscher, Ronnie B Willenheimer, John Parissis, Giedrius Gaudesius, Claudio Mori, Barbara von Eisenhart Rothe et al. · 2013 · European Journal of Heart Failure
58. Infection Risk with Bolus versus Maintenance Iron Supplementation in Hemodialysis Patients
    M. Alan Brookhart, Janet K. Freburger, Alan R. Ellis, Lily Hui-Ching Wang, Wolfgang C. Winkelmayer­, Abhijit V. Kshirsagar · 2013 · Journal of the American Society of Nephrology
59. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia
    David E. Leaf, David S. Goldfarb · 2008 · Kidney International
60. Anemia of chronic disease: A harmful disorder or an adaptive, beneficial response?
    Ryan Zarychanski, Donald Stuart Houston · 2008 · Canadian Medical Association Journal
61. Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data
    Julia Bohlius, Kurt Schmidlin, Corinne Brillant, Guido Schwarzer, Sven Trelle, Jerome Seidenfeld, Marcel Zwahlen, Mike J Clarke, Olaf Weingart, Sabine Kluge et al. · 2009 · Cochrane Database of Systematic Reviews
62. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers
    J. Malcolm O. Arnold, Jonathan G. Howlett, Paul Dorian, Anique Ducharme, Nadia Giannetti, Haissam A. Haddad, George A. Heckman, Andrew P. Ignaszewski, Debra Isaac, Philip Jong et al. · 2007 · Canadian Journal of Cardiology
63. Reticulocyte hemoglobin content
    Alan E. Mast, Morey A. Blinder, Dennis J. Dietzen · 2007 · American Journal of Hematology
64. Dialysis Fistula or Graft
    Michael Allon, Charmaine E. Lok · 2010 · Clinical Journal of the American Society of Nephrology
65. Risk Factors for Cardiovascular Events After Successful Renal Transplantation
    Yves F. Ch. Vanrenterghem, Kathleen J. Claes, Giuseppe Montagnino, Steffen Fieuws, Bart Maes, Margarita Nora Villa, Claudio E. Ponticelli · 2008 · Transplantation
66. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease
    Mai Sugahara, Tetsuhiro Tanaka, Masaomi Nangaku · 2017 · Kidney International
67. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study
    Steven Fishbane, Carol A. Pollock, Mohamed El-Shahawy, Elizabeth T. Escudero, Anjay Rastogi, Bui Pham Van, Lars Frison, Mark Houser, Maksym Pola, Dustin J. Little et al. · 2022 · Journal of the American Society of Nephrology
68. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
    Elaine Ku, Lucia Del Vecchio, Kai‐Uwe Eckardt, Volker H. Haase, Kirsten L. Johansen, Masaomi Nangaku, Navdeep Tangri, Sushrut S. Waikar, Andrzej Więcek, Michael Cheung et al. · 2023 · Kidney International
69. Diagnosis and management of anaemia of chronic disease: current status
    Jonathan Cullis · 2011 · British Journal of Haematology
70. Cardiorenal syndrome—current understanding and future perspectives
    Branko G. Braam, Jaap A. Joles, Amir H. Danishwar, Sandrine Gaillard · 2013 · Nature Reviews Nephrology
71. Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome
    Alberto Palazzuoli, Donald S. Silverberg, Francesca Iovine, Anna Calabrò, Maria Stella Campagna, Maddalena Gallotta, Ranuccio Nuti · 2007 · American Heart Journal
72. Erythropoietin, Iron Depletion, and Relative Thrombocytosis: A Possible Explanation for Hemoglobin-Survival Paradox in Hemodialysis
    Elani Streja, Csaba Pal Kovesdy, Sander Greenland, Joel D. Kopple, Charles J. McAllister, Allen R. Nissenson, Kamyar Kalantar‐Zadeh · 2008 · American Journal of Kidney Diseases
73. Cerebro-renal interactions: Impact of uremic toxins on cognitive function
    Kimio Watanabe, Tsuyoshi Watanabe, Masaaki Nakayama · 2014 · NeuroToxicology
74. Anaemia management and mortality risk in chronic kidney disease
    Walter Hermann Hörl · 2013 · Nature Reviews Nephrology
75. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study
    Francesco Locatelli, Pedro Aljama, Bernard Canaud, Adrian Constantin Covic, Angel de Francisco, Iain C. Macdougall, Andrzej Więcek, Raymond Vanholder, On behalf of the Anaemia Working Group of European Renal Best Practice (ERBP) · 2010 · Nephrology Dialysis Transplantation
76. Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated
    Wong, Michelle M Y, Tu, Charlotte, Li, Yun, Perlman, Rachel L, Pecoits-Filho, Roberto, Lopes, Antonio A, Narita, Ichiei, Reichel, Helmut, Port, Friedrich K, Sukul, Nidhi et al. · 2020 · Clinical Kidney Journal
77. An international observational study suggests that artificial intelligence for clinical decision support optimizes anemia management in hemodialysis patients
    Carlo Barbieri, Manuel Molina, Pedro Ponce, Monika Tothová, Isabella Cattinelli, Jasmine Ion Titapiccolo, Flavio Mari, Claudia Amato, Frank Leipold, Wolfgang Wehmeyer et al. · 2016 · Kidney International
78. Study designs: Part 4 – Interventional studies
    Aggarwal, Rakesh, Ranganathan, Priya · 2019 · Perspectives in Clinical Research
79. Mechanism of Increased Mortality Risk with Erythropoietin Treatment to Higher Hemoglobin Targets
    Steven N. Fishbane, Anatole Besarab · 2007 · Clinical Journal of the American Society of Nephrology
80. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis
    Suetonia C. Palmer, Valeria M. Saglimbene, Dimitris Mavridis, Georgia Salanti, Jonathan C. Craig, Marcello A. Tonelli, Natasha Wiebe, Giovanni FM Strippoli · 2014 · Cochrane Database of Systematic Reviews
81. Iron and anemia in human biology: a review of mechanisms
    Garry J. Handelman, Nathan W. Levin · 2008 · Heart Failure Reviews
82. Venous thromboembolic events in critically ill traumatic brain injury patients
    Markus B. Skrifvars, Michael Bailey, Jeffrey Presneill, Craig French, Alistair Nichol, Lorraine Little, Jacques Duranteau, Olivier Huet, Samir H. Haddad, Yaseen M. Arabi et al. · 2016 · Intensive Care Medicine
83. Associates of Mortality and Hospitalization in Hemodialysis: Potentially Actionable Laboratory Variables and Vascular Access
    Eduardo Lacson, Weiling Wang, Raymond M. Hakim, Ming Foey Teng, J. Michael Lazarus · 2008 · American Journal of Kidney Diseases
84. Novel therapeutic targets for the treatment of heart failure
    Juan Luis Tamargo, Jose Luis Lopez-Sendon · 2011 · Nature Reviews Drug Discovery
85. Left Ventricular Geometry Predicts Cardiovascular Outcomes Associated with Anemia Correction in CKD
    Kai‐Uwe Eckardt, Armin W. Scherhag, Iain C. Macdougall, Dimitrios Tsakiris, Naomi Clyne, Francesco Locatelli, Michael F. Zaug, Hans Ulrich Burger, Tilman Bernhard Drüeke · 2009 · Journal of the American Society of Nephrology
86. Cardiovascular Toxicity of Epoetin-Alfa in Patients with Chronic Kidney Disease
    Peter Andrew McCullough, Huiman Xie Barnhart, Jula K. Inrig, Donal N. Reddan, Shelly K Sapp, Uptal D. Patel, Ajay K. Singh, Lynda Anne M. Szczech, Robert M. Califf · 2013 · American Journal of Nephrology
87. Adjunctive therapy for cerebral malaria and other severe forms ofPlasmodium falciparummalaria
    Chandy C. John, Elizabeth Kutamba, Keith Mugarura, Robert Opika Opoka · 2010 · Expert Review of Anti-infective Therapy
88. Correction of Postkidney Transplant Anemia Reduces Progression of Allograft Nephropathy
    Gabriel J. Choukroun, Nassim Kamar, Bertrand Dussol, Isabelle Étienne, Élisabeth Cassuto, Olivier Toupance, François Glowacki, Bruno Moulin, Yvon Lebranchu, Guy Touchard et al. · 2011 · Journal of the American Society of Nephrology
89. Anemia: The Point of Convergence or Divergence for Kidney Disease and Heart Failure?
    Amir Kazory, Edward A. Ross · 2009 · Journal of the American College of Cardiology
90. Anemia in diabetes: marker or mediator of microvascular disease?
    Merlin C. Thomas · 2006 · Nature Reviews Nephrology
91. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis
    Peter van der Meer, Hessel F. Groenveld, James L. Januzzi, Dirk Jan van Veldhuisen · 2009 · Heart
92. Anemia in chronic kidney disease
    Meredith A. Atkinson, Bradley A. Warady · 2017 · Pediatric Nephrology
93. Anemia in renal disease: Diagnosis and management
    Christina E. Lankhorst, Jay B. Wish · 2009 · Blood Reviews
94. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease
    Edouard R. Martin, Mark T. Smith, Bradley J. Maroni, Qing Zuraw, Emil M. deGoma · 2017 · American Journal of Nephrology
95. Erythropoietic stress and anemia in diabetes mellitus
    Dhruv K. Singh, Peter H. Winocour, Ken Farrington · 2009 · Nature Reviews Endocrinology
96. Anemia in the Elderly: How Should We Define It, When Does It Matter, and What Can Be Done?
    David P. Steensma, Ayalew Tefferi · 2007 · Mayo Clinic Proceedings
97. Differentiating Factors Between Erythropoiesis-Stimulating Agents: An Update to Selection for Anaemia of Chronic Kidney Disease
    Walter H. Hörl · 2013 · Drugs
98. Erythropoietin Action in Stress Response, Tissue Maintenance and Metabolism
    Yuanyuan Zhang, Li Wang, Soumyadeep Dey, Mawadda Alnaeeli, Sukanya Suresh, Heather Marie Rogers, Ruifeng Teng, Constance Tom Noguchi · 2014 · International Journal of Molecular Sciences
99. Hemorheology and Microvascular Disorders
    Young Il Cho, Daniel J. Cho · 2011 · Korean Circulation Journal
100. The roles of HIF-1α signaling in cardiovascular diseases
     Tatsuyuki Sato, Norihiko Takeda · 2022 · Journal of Cardiology